Department of Anesthesiology, College of Physicians and Surgeons of Columbia University, New York, NY 10032-3784, USA.
J Am Soc Nephrol. 2012 Feb;23(2):266-80. doi: 10.1681/ASN.2011050503. Epub 2011 Nov 17.
Activation of the sphingosine 1-phosphate receptor 1 (S1P(1)R) protects against renal ischemia-reperfusion (IR) injury and inflammation, but the role of other members of this receptor family in modulating renal IR injury is unknown. We found that a selective S1P(2)R antagonist protected against renal IR injury in a dose-dependent manner. Consistent with this observation, both S1P(2)R-deficient mice and wild-type mice treated with S1P(2)R small interfering RNA had reduced renal injury after IR. In contrast, a selective S1P(2)R agonist exacerbated renal IR injury. The S1P(2)R antagonist increased sphingosine kinase-1 (SK1) expression via Rho kinase signaling in renal proximal tubules; the S1P(2)R agonist decreased SK1. S1P(2)R antagonism failed to protect the kidneys of SK1-deficient mice or wild-type mice pretreated with an SK1 inhibitor or an S1P(1)R antagonist, suggesting that the renoprotection conferred by S1P(2)R antagonism results from pathways involving activation of S1P(1)R by SK1. In cultured human proximal tubule (HK-2) cells, the S1P(2)R antagonist selectively upregulated SK1 and attenuated both H(2)O(2)-induced necrosis and TNF-α/cycloheximide-induced apoptosis; the S1P(2)R agonist had the opposite effects. In addition, increased nuclear hypoxia inducible factor-1α was critical in mediating the renoprotective effects of S1P(2)R inhibition. Finally, induction of SK1 and S1P(2)R in response to renal IR and S1P(2)R antagonism occurred selectively in renal proximal tubule cells but not in renal endothelial cells. Taken together, these data suggest that S1P(2)R may be a therapeutic target to attenuate the effects of renal IR injury.
S1P1 受体的激活可防止肾缺血再灌注(IR)损伤和炎症,但该受体家族的其他成员在调节肾 IR 损伤中的作用尚不清楚。我们发现,一种选择性的 S1P2R 拮抗剂可呈剂量依赖性地保护肾免受 IR 损伤。与这一观察结果一致,S1P2R 缺陷型小鼠和用 S1P2R 小干扰 RNA 处理的野生型小鼠在 IR 后肾损伤减少。相反,选择性的 S1P2R 激动剂加剧了肾 IR 损伤。S1P2R 拮抗剂通过 Rho 激酶信号增加肾近端小管中的鞘氨醇激酶-1(SK1)表达;S1P2R 激动剂降低 SK1。S1P2R 拮抗剂不能保护 SK1 缺陷型小鼠或用 SK1 抑制剂或 S1P1R 拮抗剂预处理的野生型小鼠的肾脏,表明 S1P2R 拮抗剂赋予的肾脏保护作用是通过 SK1 激活 S1P1R 所涉及的途径产生的。在培养的人近端肾小管(HK-2)细胞中,S1P2R 拮抗剂选择性地上调 SK1,并减轻 H2O2 诱导的坏死和 TNF-α/环已酰亚胺诱导的凋亡;S1P2R 激动剂则有相反的作用。此外,增加核缺氧诱导因子-1α是介导 S1P2R 抑制的肾保护作用的关键。最后,肾 IR 及 S1P2R 拮抗作用诱导的 SK1 和 S1P2R 选择性地在肾近端小管细胞中而不是在肾内皮细胞中发生。总之,这些数据表明 S1P2R 可能是减轻肾 IR 损伤作用的治疗靶点。